Nikolic, Nikola (58541091700)Nikola (58541091700)NikolicGolubovic, Aleksa (58258139500)Aleksa (58258139500)GolubovicRatkovic, Ana (58541092000)Ana (58541092000)RatkovicPandurevic, Srdjan (57198424533)Srdjan (57198424533)PandurevicKontic, Milica (43761339600)Milica (43761339600)Kontic2025-07-022025-07-022023https://doi.org/10.1016/j.cllc.2023.04.010https://www.scopus.com/inward/record.uri?eid=2-s2.0-85160110807&doi=10.1016%2fj.cllc.2023.04.010&partnerID=40&md5=b782dce510e5b7240eff081d09af6af9https://remedy.med.bg.ac.rs/handle/123456789/11766• PDL1 expression is a widely used biomarker in selecting patients suitable for immunotherapy. • PDL1 expression over 50% is considered a good predictive biomarker in patients with NSCLC. • New guidelines recommend combination immune and chemotherapy as first line treatment in patients with PDL1 over 1% (including patients with TPS over 50%). • Stratification of patients over 50% of PDL1 expression and response to treatment has not been done. • In our study we showed that very high PDL1 expression (over 80%) is a good predictive biomarker for response to ICI. • Several studies confirmed our results with a relatively small sample size, therefore this could be the guideline for future studies. • Would patients with TPS over 80% benefit more from mono immunotherapy, and patients under that mark from combination immune and chemotherapy? © 2023 Elsevier Inc.